Go back to the main page.
Transforming Today's Science Into Tomorrow's Cures
Samaritan's collaborative researchers have made important patented discoveries in the fields of, central nervous system diseases, such as, Alzheimer's disease; cancer; cardiovascular disease; and infectious diseases, such as, AIDS, and Hepatitis C. These discoveries have positioned us with a rich pipeline of new drugs with novel mechanisms of actions to develop.
Samaritan Pharmaceuticals, Inc. is an entrepreneurial biopharmaceutical company focused on the development and marketing of innovative therapeutics. At Samaritan Pharmaceuticals our mission has been to create life-saving drugs for people suffering from AIDS, Alzheimer’s, heart disease and cancer. View all the latest press releases and news articles focused on Samaritan Pharmaceuticals, Inc. These publications, called peer-reviewed journals, are scholarly periodicals requiring each article submitted be judged by an independent panel of experts (scientific peers) to authenticate the accuracy of the material. The number of articles printed and the variety of publications accepting the article serve to underscore the legitimacy of information. Samaritan has collaborative relationships with other pharmaceutical companies to commercialize branded approved prescription products in selected niche territories, such as, in Greece, Albania, Bosnia, Bulgaria, Croatia, Cyprus, Czech Republic, Egypt, FYROM, Hungary, Montenegro, Poland, Romania, Serbia, Slovakia, Slovania, Syria and Turkey. Before a drug can be offered to the public it must go through several phases of rigorous testing to make sure it is safe, efficient and does what it says it can do. The testing is mandated and overseen by the U.S. Food and Drug Administration (FDA) which is part of the U.S. Department of Health and Human Services. SAMARITAN PIPELINE - (MECHANISM OF ACTION VIDEOS)
Go back to the main page. Contact Samaritan Pharmaceuticals, Inc. Find what you are looking for in our website.

SP-1000:
CARDIOVASCULAR DISEASE DRUG
An 8-amino acid peptide indicated in cardiovascular diseases.

Capabilities:
  1. Eliminates free cholesterol from serum (blood)
  2. Attacks soft and hard plaque without damaging the aorta, thereby decelerating plaque buildup
  3. Lowers elevated LDL and VLDL levels
  4. Raises sub-optimal HDL levels
  5. May be administered as a stand-alone therapeutic or in combination
  6. Has a high affinity for cholesterol, readily binding free serum cholesterol and creating a non-toxic compound that can not be re-absorbed in the intestines and is eliminated by the liver

Significance: Coronary artery disease (CAD) is caused by atherosclerosis (the thickening and hardening of the inside walls of arteries). In atherosclerosis, plaque deposits build up in the arteries. Plaque is made up of fat, cholesterol, calcium, and other substances from the blood. CAD, the most common heart disease, may lead to one of several conditions.

- Angina - Heart Attack
- Heart Failure - Arrhythmia

Current Treatments: There are several approved treatments for CAD, each is directed at addressing a specific aspect of the disease: cholesterol lowering drugs, blood thinners, beta-blockers, angiotensin and coronary angioplasty.

SP-1000 Advantage: SP-1000 is a self-regulating cholesterol modulator lowering elevated LDL and VLDL levels and raising sub-optimal HDL levels to within normal ranges. It is a fast acting (within 48 hrs.) cholesterol clearing drug promising to completely remove deadly plaque from clogged arteries safely and effectively.


SP-1000 is a peptide that can be used to clean the blood of excessive cholesterol in acute high cholesterol conditions. SP-1000 plays a role in transformation and binding of LDL cholesterol and raising HDL, the good cholesterol, with immediate results.

To this end, Samaritan's collaborating scientists developed SP-1000 to be a potentialy pocholesterolemic agent that acts through a new and novel mechanism of action that is quite distinct to the mechanism mediating the effects of statins.

The effectiveness of SP-1000 peptide treatment has been demonstrated in two validated hypercholesterolemia animal models, a genetically engineered mouse model mimicking familial hypercholesterolemia, and in diet-induced hypercholesterolemia in guinea pigs.

Based on the study results, Samaritan collaborative scientists believe that the SP-1000 peptide could have the following pharmacological activities:

  • SP-1000 peptide will not interfere with cholesterol metabolism and disposition
  • SP-1000 peptide will increase HDL while decreasing serum free cholesterol and total bile cholesterol
  • SP-1000 peptide will be effective in removing atheromas and preventing plaque formation
  • SP-1000 peptide will protect against high cholesterol-induced neurological, cardiac and muscular suffering, and gross liver morphology

Taken together, these data on classic animal models of familial and dietary hypercholesterolemia show that SP-1000 is an interesting new and novel lipid lowering drug with a strong patent position that represents a competitive advantage over currently available therapeutic options whether marketed alone and/or in combination with another cholesterol lowering drug.